Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.99% to $684.87 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.76% to ...

The Mineola Board of Education recognized Fatimah Badoolah, a senior at Mineola High School, who is a 2025 Regeneron Science ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...